Cytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the Year
Key Highlights
- ➤Cytek Aurora Evo wins 2026 Drug Discovery Innovation of the Year award
- ➤Aurora Evo cuts plate-well acquisition time approximately 40% versus earlier generations
- ➤Aurora Evo adds automated startup and shutdown to reduce operator intervention
- ➤Aurora Evo is being developed toward robotic-arm automated sample processing
- ➤Instrument harmonization supports reproducible results across systems, laboratories and time
Expert Statements
Bryan Vaughn, Managing Director, BioTech Breakthrough
“The Cytek Aurora Evo system is helping transform life sciences research by addressing the growing need for higher throughput, greater automation and reproducible data”
Bryan Vaughn, Managing Director, BioTech Breakthrough
“By bringing these capabilities together without compromising flexibility or data quality, the system helps pharmaceutical and CRO laboratories scale high-parameter spectral flow cytometry across increasingly complex research workflows.”
Wenbin Jiang, Ph.D., CEO of Cytek Biosciences
“Modern drug discovery requires technologies that support increasingly complex experiments while helping laboratories work more efficiently and generate consistent, reliable data”
Wenbin Jiang, Ph.D., CEO of Cytek Biosciences
“The Cytek Aurora Evo system addresses these needs by combining higher throughput and automation with the proven performance and reproducibility of the Cytek Aurora platform.”
Wenbin Jiang, Ph.D., CEO of Cytek Biosciences
“This recognition reflects our continued commitment to advancing flow cytometry to meet the evolving needs of researchers.”
FREMONT, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that its Cytek Aurora(®) (link) Evo system has been named Drug Discovery Innovation of the Year in the 2026 BioTech Breakthrough Awards. The annual program recognizes innovative companies, products and services across the life sciences and biotechnology industries.
As pharmaceutical companies and contract research organizations (CROs) expand the use of high-parameter spectral flow cytometry in drug discovery and applied research, they face growing demands for sample throughput, automation and consistent data across instruments and research sites. The Cytek Aurora Evo system builds on the established performance of the Cytek Aurora(®) platform with enhancements designed to help laboratories scale complex research workflows without compromising data quality.
Get started
Create a free account to read the full story.